Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3821-3840 of 3,900 trials

Chikungunya Vaccine: Effectiveness and Safety Study

We are evaluating how well the chikungunya vaccine works in preventing severe disease and hospitalizations in at-risk populations. This study aims to understand the vaccine's real-life impact on health outcomes.

Chikungunya1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Lactose Intolerance: Gaxilose Oral Treatment

We are testing a new oral treatment called Gaxilose in healthy adults to see if it improves the body's ability to digest lactose. This study aims to understand its potential benefits for those with lactose intolerance.

Lactose Intolerance3-6 monthsSafety phase (I)Gastroenterology

Axial Spondyloarthritis: EAST-1 Trial

We are investigating a new treatment that targets ERAP inhibition for individuals with axial spondyloarthritis. The goal is to see if this approach improves symptoms compared to standard care.

Axial Spondyloarthritis6-12 monthsSafety phase (I)Rheumatology

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Cerebrolysin for Recovery After Ischemic Stroke

We are studying whether Cerebrolysin can improve upper limb function and overall recovery in patients after an ischemic stroke. Participants will be compared to those receiving a placebo to assess various health outcomes.

Ischaemic Stroke3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Parkinson's Disease: New Investigational Compound

We are investigating a new treatment for Parkinson's disease in both healthy individuals and patients. The goal is to assess its safety and effectiveness in managing neurological symptoms.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Atrial Fibrillation: AP31969 Medication Study

We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.

Atrial Fibrillation3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Chronic Dialysis: Patiromer for Potassium Management

We are studying whether patiromer can help patients on chronic dialysis eat more potassium-rich foods safely. This trial looks at its impact on health-related quality of life and dietary restrictions.

End Stage Kidney DiseaseConfirmation phase (III)Investigational MedicinesNephrology

Nirogacestat: Understanding Its Effects in Healthy Men

We are studying how the drug Nirogacestat affects liver enzymes in healthy men. This research may help us understand its safety and how it works in the body.

Fibromatosis3-6 monthsSafety phase (I)DermatologyInternal Medicine

Olmsted Syndrome: KM-023 Treatment Study

We are testing a new treatment called KM-023 in healthy volunteers and patients with Olmsted syndrome. The goal is to learn about its safety and how it may help those affected by this condition.

Olmsted Syndrome6-12 monthsSafety phase (I)Dermatology

Colonoscopy Prep: Mannitol vs. Plenvu®

We are studying whether mannitol is as effective and acceptable as Plenvu® for bowel preparation before a colonoscopy. This trial aims to ensure patient comfort and safety during the procedure.

Colonoscopy3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterology

Covert Brain Infarction: Antiplatelet and Lipid-Lowering Treatments

We are studying whether adding antiplatelet and cholesterol-lowering medications can help patients with covert brain infarctions reduce serious health risks. This trial will also assess the impact on cognitive health and overall mortality.

Covert Brain Infarct>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Immunotherapy for High-Risk Oral Disorders: APHRODITE Trial

We are testing a new immunotherapy to see if it can prevent high-risk oral disorders from turning into cancer. The study will also look at the treatment's safety and its effects on patients' quality of life.

Oral Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Long-term Safety Study of GD2IL18CART Treatment

We are following up with patients who received GD2IL18CART to check for any long-term safety concerns and to see how well the treatment is working over time, especially in children.

NeuroblastomaOsteosarcomaEwing's Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Quabodepistat: Understanding Liver Function Impact

We are studying how Quabodepistat is processed in adults with reduced liver function versus those with normal liver function. This research may help improve treatment safety and effectiveness for individuals with liver conditions.

Tuberculosis6-12 monthsSafety phase (I)HepatologyInfectious Diseases

Leriglitazone: Drug Interaction Study

We are studying how the new drug leriglitazone interacts with other medications and food in healthy men. This research may help us understand its safety and effectiveness when taken with certain drugs or after a high-fat meal.

AdrenoleukodystrophySafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

Metastatic Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are studying a new drug, BMS-986504, combined with pembrolizumab and chemotherapy for patients with metastatic non-small cell lung cancer and a specific genetic deletion. The goal is to see if this combination improves survival compared to a placebo treatment.

Metastatic Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNephrology

Migraine Study: Effects of Cilostazol

We are investigating how cilostazol affects migraine headaches in men and women without aura. The study looks at potential differences in response based on sex.

Migraine6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurology